Towards a mechanistic understanding of reciprocal drug-microbiome interactions. by Zimmermann, Michael et al.
Review
Towards a mechanistic understanding of reciprocal
drug–microbiome interactions
Michael Zimmermann1,* , Kiran Raosaheb Patil1,2 , Athanasios Typas1,3 & Lisa Maier4,5,**
Abstract
Broad-spectrum antibiotics target multiple gram-positive and
gram-negative bacteria, and can collaterally damage the gut
microbiota. Yet, our knowledge of the extent of damage, the
antibiotic activity spectra, and the resistance mechanisms of gut
microbes is sparse. This limits our ability to mitigate microbiome-
facilitated spread of antibiotic resistance. In addition to antibi-
otics, non-antibiotic drugs affect the human microbiome, as shown
by metagenomics as well as in vitro studies. Microbiome–drug
interactions are bidirectional, as microbes can also modulate
drugs. Chemical modifications of antibiotics mostly function as
antimicrobial resistance mechanisms, while metabolism of non-
antibiotics can also change the drugs’ pharmacodynamic, pharma-
cokinetic, and toxic properties. Recent studies have started to
unravel the extensive capacity of gut microbes to metabolize
drugs, the mechanisms, and the relevance of such events for drug
treatment. These findings raise the question whether and to which
degree these reciprocal drug–microbiome interactions will differ
across individuals, and how to take them into account in drug
discovery and precision medicine. This review describes recent
developments in the field and discusses future study areas that
will benefit from systems biology approaches to better understand
the mechanistic role of the human gut microbiota in drug actions.
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Introduction
Our understanding of how the human gut microbiota contributes
to health and disease, and how it changes over time, life stages,
different geographic regions, and in response to environmental
factors has increased dramatically over the last decade (The
Integrative HMP (iHMP) Research Network Consortium, 2019;
Pasolli et al, 2019; Nayfach et al, 2019; Falony et al, 2016). The
current consensus is that the gut microbiome has a highly individ-
ualized composition, especially at the bacterial strain level (Fran-
zosa et al, 2015). Further, healthy individuals retain a largely
stable microbiota composition for most of their adulthood (Som-
mer et al, 2017; Mehta et al, 2018). This composition is estab-
lished in early stages of life (B€ackhed et al, 2015; Wampach et al,
2017) and is dependent more on the environment than on host
genetics (Rothschild et al, 2018). Hence strong perturbations, such
as dietary shifts and antibiotic consumption, can unbalance micro-
biome stability, with so far unpredictable recovery (Willing et al,
2011; Falony et al, 2016; Lynn et al, 2018). On the other hand,
chemical modification of therapeutic compounds by intestinal
bacteria can influence the therapeutic effect of drugs (Fig 1). We
have only recently begun to explore these complex, bidirectional
interactions between our resident microbes and medication. In this
review, we provide an overview of the different systems-level
approaches that can be employed to gain insights into the drug–
microbiome–host triad (Fig 2). A better and more systematic
understanding of these interactions and their underlying molecular
constituents can be instrumental for diagnostic, prognostic, and
ultimately, therapeutic applications.
Therapeutic drugs alter the gut microbiome composition
Evidence from metagenomic-based cohorts and clinical
studies—the top-down approach
Exploring the factors that explain inter-individual differences in
the intestinal microbiome composition across large population
cohorts have repeatedly identified medication as a main contribu-
tor (Falony et al, 2016; Ticinesi et al, 2017; Jackson et al, 2018;
Vich Vila et al, 2020). Although such studies have been insightful
and have revealed the cumulative and dramatic impact medication
has on the gut microbiome composition, they are still underpow-
ered for separating the effects of individual drug classes. To begin
stratifying these effects, one can broadly separate drugs to antimi-
crobials, developed to target microbes, and to drugs designed to
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interact with human/host targets, here referred to as human-
targeted drugs.
Antimicrobial drugs comprise antibiotics, antifungals, antiproto-
zoals, antivirals, and anti-archaeals. These compounds target
proteins that are typically absent in the host or are clearly distin-
guishable from their human homologues, yet they are often
present in commensal microbes colonizing the human body. As a
consequence, antimicrobials can “collaterally damage” the micro-
biome and thereby have mild to severe side effects to patients
(Kuhn et al, 2016). This has been best studied for antibiotics, with
clinical and animal studies illustrating changes in the gut micro-
biome composition and physiological host parameters, such as
metabolic, cognitive, and immune functions (Cho et al, 2012; Cox
et al, 2014; Hwang et al, 2015; Fröhlich et al, 2016; Hagan et al,
2019). Initial data indicate that the microbiota of healthy patients
can partially rebound post-antibiotic treatment (Rashid et al, 2015;
Palleja et al, 2018). However, it remains unclear whether this is
true for a broader and/or more diverse population, and what are
the links to antibiotic classes, initial microbiome composition and
treatment duration. Similarly, our knowledge on the target spectra,
mode of action, and resistance mechanisms of the different classes
of antibiotics and their specific effect on gut commensal bacterial
species is scarce (preprint: Maier et al, 2020). To gain mechanistic
insights into these matters, assays, tools, and test systems from
decades of antibiotic research on pathogens can be capitalized and
adapted to study gut commensal species in pure culture, within
microbial communities and within the host, especially at a system-
atic level (Fig 2) (Maier & Typas, 2017). Such detailed mechanistic
knowledge can help design better and more precise strategies to
prevent or revert antibiotics-caused "collateral damage," which at
the moment are based on generic processes with limited success
and/or adverse outcomes, such as fecal transplantation or adminis-
tration of probiotics (Zmora et al, 2018; Suez et al, 2018; DeFilipp
et al, 2019) (Box 2).
For host-targeted drugs, increasing evidence suggests that they
are associated with shifts in gut microbiome composition. Known
examples span a broad range of therapeutic classes and include
the antidiabetic metformin, proton-pump inhibitors, antipsychotics,
non-steroidal anti-inflammatory drugs, paracetamol, opioids, selec-
tive serotonin reuptake inhibitors, laxatives, and statins (Le
Bastard et al, 2018; Jackson et al, 2018; Kummen et al, 2020;
MetaCardis Consortium et al, 2020). These shifts are not necessar-
ily unfavorable for the host. In certain cases, host-targeted drugs
can diversify the gut microbiome (MetaCardis Consortium et al,
2020)—a feature generally linked to a healthy microbiome.
However, the functional implications of these taxonomic shifts, for
example in terms of altered metabolic capacities and/or antibiotic
resistance repertoires, need to be assessed separately for each
compound (Vich Vila et al, 2020).
Current clinical studies of the effects of medication on the gut
microbiome have mostly been cross-sectional, while interventional
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Figure 1. Overview on the drug–microbiome–host triad and their interactions.
Left: The intake of drugs can have a direct influence on individual members of the gut microbiome (classic example: antibiotics) but can also change the composition
and functionality of the microbiome through indirect, host-mediated ways (example: proton-pump inhibitors, which might alter the microbiome composition by
increasing the gastric pH). Right: Intestinal bacteria can modify and metabolise drugs. In addition, the microbiome can indirectly modulate host xenobiotic metabolism
in the liver. Furthermore, there is crosstalk between all these interactions. Ultimately, these complex interactions can possibly have negative health consequences and
cause interpersonal differences in treatment outcomes.
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diseased control groups are often missing. As a result, it is difficult
to differentiate between disease-mediated and drug-related effects.
This issue is exemplified by the antidiabetic drug metformin. The
drug shows limited oral bioavailability, resulting in high intestinal
drug concentration. It was one of the first non-antibiotic drugs that
was shown to influence gut microbiome composition (Napolitano
et al, 2014) and revealed the need to stratify for treatment when
interpreting microbiome signatures (Forslund et al, 2015). At the
same time, this finding stimulated causal studies that directly linked
compositional shifts to the improvement of metabolic dysfunction
and hyperglycemia (Wu et al, 2017). One proposed mechanism
involves metformin decreasing the relative abundance of Bacteroides
fragilis and downregulating its associated bile salt hydrolase activ-
ity. This leads to an accumulation of glycoursodeoxycholic acid,
which inhibits the intestinal farnesoid X receptor (FXT) signaling
and thereby improves various metabolic outcomes in mice, includ-
ing hyperglycemia (Sun et al, 2018). Other proposed mechanisms to
explain the microbiome-mediated hypoglycemic effect of metformin
include the microbial production of short-chain fatty acids, promo-
tion of gut barrier integrity and increased secretion of gut hormones
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Figure 2. Systems approaches to study drug–microbiome–host interactions.
Left: A wide variety of model systems can be used to study drug–microbiome–host interactions. On the microbial side, (possibly genetically modified) isolates in pure
culture or synthetic or stool-derived microbial communities are applied. On the host side, simple cell culture systems, intestinal organoids but also different animal
models can be employed. Right: Diverse technologies help to decipher drug–microbiome–host interactions. Approaches can be broadly divided into phenotypic
characterization, OMICs approaches, and model-based predictions. Depending on the research question, appropriate model systems and suitable technologies can be
combined. TPP: thermal proteome profiling, LiP-MS: limited proteolysis-coupled mass spectrometry.
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such as glucagon-like peptide 1 and peptide YY (PYY) (reviewed in
Pryor et al, 2020). Remarkably, several model systems such as
Caenorhabditis elegans (Cabreiro et al, 2013), mice (Shin et al,
2014), and rats (Bauer et al, 2018) were instrumental in elucidat-
ing these metformin–microbiome–host interactions, highlighting
the translation of these phenomena between evolutionarily
distant organisms and demonstrating the utility of different model
organisms to study these interactions. In contrast to metformin,
we are far from dissecting the interaction of the vast majority of
host-targeted drugs with gut microbes. It remains unclear
whether these drugs act directly on the microbes, what is their
spectrum and underlying molecular interactions, and what is the
impact on the microbiome as a whole, on the drug’s therapeutic
action and on the host. To close this knowledge gap and opti-
mize drug therapies, further well-designed clinical studies are
needed, which must be seamlessly coordinated with bottom-up
approaches (Fig 2).
Ex vivo studies—accelerating mechanistic understanding of
drug–microbiome interactions by reducing the complexity and
increasing the throughput—the bottom-up approach
While clinical studies provide an excellent global picture of drug
effects on the microbiome, ex vivo approaches allow for a system-
atic, controlled, and question-specific dissection of these interac-
tions at various scales ranging from molecules to inter-organismal
interactions. Recent advances in high-throughput approaches for the
cultivation of fastidious anaerobes (Box 1) allowed the first system-
atic studies of the effects of drugs on intestinal microbes. A large-
scale in vitro screen of 1,200 marketed drugs showed direct impact
on the growth of at least one of forty tested human gut commensal
species for 78% of the antibacterial drugs, 53% of other antimicro-
bials, and 24% of the human-targeted drugs (Maier et al, 2018).
Although drugs across all therapeutic classes had a direct impact on
gut commensal species, the effect was most pronounced for
antimetabolites, antipsychotics, and calcium-channel blockers.
Some of these compounds, such as antimetabolites, target
conserved enzymes and pathways in prokaryotes and eukaryotes
and thus, likely have the same mode of action in gut commensals as
in host cells. However, for the vast majority of human-targeted
drugs with activity against gut bacteria, their bacterial targets
remain obscure. Identifying microbial targets for these drugs will
open new possibilities for repurposing them as antibacterials and/or
for mitigating their collateral damage on gut bacteria. Intriguingly,
human-targeted drugs impacting microbes in vitro resembled antibi-
otics with respect to their reported side effects in clinics, providing
initial evidence that they also impact gut commensals in vivo. More-
over, antibiotic-resistant microbes were in general also more resis-
tant to human-targeted drugs, suggesting that resistance
mechanisms against antibiotics and non-antibiotics at least partially
overlap. Initial profiling of these common resistance mechanisms
revealed efflux pumps, transporters and detoxifications mecha-
nisms. Other activities, such as cell envelope properties, stress
responses and target modification are also likely involved. Precisely
mapping this level of cross-resistance and collateral sensitivity (i.e.,
resistance to one drug providing sensitivity to another) is vital to
mitigate the risks human-targeted drugs may entail for antibiotic
resistance and to exploit collateral sensitivity opportunities to delay,
prevent or revert antibiotic resistance (Pal et al, 2015; Baym et al,
2016). To this end, a number of established systems approaches can
be specifically geared to deconvolute drug targets and reveal resis-
tance mechanism, as demonstrated for chemical genetics (Cacace
et al, 2017; Kintses et al, 2019), proteomics (thermal proteome pro-
filing (Mateus et al, 2020), limited proteolysis-coupled mass spec-
trometry (Schopper et al, 2017), and metabolomics (Zampieri et al,
2018) (Fig 2).
The numerous interactions observed between human-targeted
drugs and gut microbes in vitro beg the question of whether they
are relevant in vivo. For example, it is unclear whether microbes
alone similarly respond to drugs as when part of a community,
and how the spatially structured intestinal environments and
drug concentration gradients inside the host affect drug response.
One way to leverage drug–microbiome interactions to the
community level is to test assembled (“synthetic”) communities
(Box 1). Microbes can behave the same in communities as in an
axenic culture (the drug being as effective against them) or can
have communal emergent properties: be more protected (cross-
protection) or sensitized (cross-sensitization) to the drug. It is
currently unclear how often such emerging communal properties
occur and/or what drives them. Drug chemical modification can
lead to both cross-protection (Vega & Gore, 2014) and cross-
sensitization (Roemhild et al, 2020), but also other less direct
effects could elicit similar results: the change in physiological
stage of the bacterial cells (e.g., stress responses and transporters
induced at the community level), changes of environment
(i.e., pH changes (Ratzke & Gore, 2018)), or the opening of
niches in a competitive environment. To investigate such
responses systematically, robust high-throughput ways are needed
to grow communities (Box 1) and to follow species abundance,
ideally at an absolute quantification level (e.g., by metaproteomics
(Li et al, 2020), Fig 2). Understanding the frequency and molecu-
lar drivers of such interactions will be of paramount impor-
tance to exploit or mitigate microbiome-mediated drug effects in
clinics (Fig 3).
Microbiome effects on drugs
Microbes alter the chemistry of drugs and drug metabolites
Given the structural similarity between small molecule drugs and
endogenous metabolites, the fact that many drugs are derived from
natural products, and the large enzymatic potential of the micro-
biome, microbial drug metabolism is to be expected. Indeed,
already in the early 20th century the drug prontosil was found to
require bacterial conversion to unfold its antibiotic effects (Fuller,
1937). Since then, accumulating evidence suggests that microbial
modification of drugs and drug metabolites seems to be the rule
rather than the exception. Such microbial drug metabolism can
result in the same or different chemical products as the human
metabolic enzymes, leading to drug activation (e.g., sulfasalazine,
Sousa et al, 2014), inactivation (e.g., L-dopa and digoxin (Linden-
baum et al, 1981; Haiser et al, 2013; Maini Rekdal et al, 2019)) or
toxicity (e.g., sorivudine and brivudine, (Zimmermann et al, 2019a;
Nakayama et al, 1997). In addition to drug molecules, drug
metabolites are also subject to microbial metabolism. Phase II drug
metabolites (produced by conjugation reactions) have been found
to be deconjugated to their precursor molecules (i.e., phase I
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metabolites (Wallace et al, 2010) or original drug molecules (Taylor
et al, 2019)) by microbes. More importantly, these types of micro-
bial metabolism can impact pharmacokinetics, in particular the
intestinal abundance of drug and drug metabolites, and thereby
alter drug response and toxicity (Wallace et al, 2010; Taylor et al,
2019). Since differences in microbiome-encoded genetic contents
far exceed genetic differences between human individuals, it is very
likely that the microbiota composition may be behind a large frac-
tion of person-to-person variation in drug response, especially in
terms of drug side effects. In the following paragraphs, we will
discuss various approaches to investigate microbiome drug metabo-
lism, its impact on drug response and potential avenues to harness
Box 1. Representative microbes and microbiomes
A: Representative microbes
The significance of systemic mapping of drug–microbiome interactions increases with the number of representative microbes tested. Consequently,
comprehensive species and strain collections are essential. The benefit of such collections further increases, the better the isolates are characterized
(e.g., genome sequence), and the more detailed metadata information is provided (e.g., health status of the host).
Gut microbiome isolate collections
The compilation of such collections usually follows certain selection criteria—such as being representative for the gut microbiome of healthy individu-
als—and focuses on type strains, which are obtained from publicly available strain collections such as DSMZ, ATCC/BEI Resources, etc. (www.dsmz.de,
http://www.atcc.org, www.beiresources.org) (e.g., Tramontano et al, 2018). Further collections are needed that are representative for other body sites,
certain diseases, age-groups, ethnicities, food preferences, etc.. While most concentrate on maximizing phylogenetic diversity of prevalent and abun-
dant species, for a global picture it is also important to capture rare species and species diversity (i.e., strain-level variation).
Strain-level variation
Current studies only phenotype one or few strains per species, usually starting with type strains. For most tested species, it is unknown how represen-
tative they are. Although pangenomes can be estimated for many gut species (Zou et al, 2019), it is unclear how this translates into phenotypic varia-
tion. However, previous work suggests that drug metabolism and drug sensitivity are strain-specific traits (Koppel et al, 2018; preprint: Maier et al,
2020) and that functional strain differences can impact human health. Such observations underline the importance of sampling many strains per bac-
terial species. Several efforts have been recently made toward this aim by collecting hundreds of human gut bacterial isolates. In the future, such col-
lections need to continue expanding to cover strain and species diversity—for example, many unknown species are predicted from metagenome-
assembled genomes (Almeida et al, 2019; Pasolli et al, 2019; Nayfach et al, 2019).
Recent examples for such libraries include:
1 Broad Institute-OpenBiome Microbiome Library (Poyet et al, 2019).
2 Culturable Genome Reference (CGR) Collection (Zou et al, 2019).
3 Human Gastrointestinal Bacteria Culture Collection (HBC) (Forster et al, 2019).
4 Global Microbiome Conservancy (http://microbiomeconservancy.org).
Collection of coexisting isolates from the same host
Instead of collecting and phenotyping strains from a large number of different individuals, strain collections can originate from a single person (Good-
man et al, 2011; Coyne et al, 2014). As these co-resident strains are collected from the same human host, they capture the co-evolved and coexisting
strain-level diversity within one individual. Personalized collections are of particular value for investigations of inter-individual differences in drug–mi-
crobiome interactions.
B: Microbiomes
The number of different community compositions to be examined scales almost infinitely. To tackle this challenge, two fundamentally different
approaches can be pursued: synthetic communities can be assembled starting from axenic bacterial cultures (bottom-up approach) or natural, self-
assembled communities, e.g., derived from human stool can be utilized (top-down approach).
Synthetic communities
Reductionist consortia of defined organisms are assembled in modular ways, either donor-specific or pooled. Individual community members are usu-
ally well-characterized and ideally genetically tractable. Systematic manipulations of the strain and genetic composition of synthetic communities
enable the identification of causal links between the composition and observed community phenotypes (Shetty et al, 2019).
Stoolbanks
Stool samples provide a non-invasive starting point for studying the complex, self-assembled human microbiome (Bolan et al, 2016) and can be incu-
bated with drugs ex vivo (Maurice et al, 2013; van de Steeg et al, 2018). Recently, so-called “stoolbanks” became more sophisticated in order to pro-
mote accessibility to fecal microbiota transplantation in clinical practice (Cammarota et al, 2019). But they can also be used for research purposes,
especially if they are open-access and non-profit, such as OpenBiome. Subsequent microbiome preservation efforts aim for long-term storage: for
example, the “The Microbiota Vault” (www.microbiotavault.org) is a project to conserve the microbial diversity associated with our bodies and environ-
ments for future generations.
In both setups, key functional and compositional profiles of the gut microbiota need to be maintained, for example in continuous flow bioreactor sys-
tems or microfluidic gut models (Guzman-Rodriguez et al, 2018). As these technically laborious systems are challenging to adapt to high-throughput
workflows, continuous dilution batch cultures in multi-well formats have been successfully applied to screen drug effects on microbial communities
(Venturelli et al, 2018; Li et al, 2019).
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microbiome drug metabolism to improve therapeutic drug interven-
tions. The latter would undoubtedly present an opportunity for the
pharmaceutical industry and precision medicine applications in
clinics.
Systematic studies reveal extensive microbial drug metabolism
A compound’s metabolism in the human body is a decisive factor
for its success during preclinical and clinical drug development. To
assess drug metabolism early in drug discovery pipelines, numerous
in vitro and in silico protocols have been developed and standard-
ized. New technologies, such as microfluidics screens and machine
learning predictions have been recently incorporated in such pipeli-
nes (Kirchmair et al, 2015; Eribol et al, 2016). The use of cellular or
cell-free enzyme preparation (e.g., cytosolic and microsome isola-
tions) enables systematic ex vivo high-throughput screens for the
metabolism of hundreds of compounds in parallel (Williamson et al,
2017; Underhill & Khetani, 2018). The results of such systematic
assays, together with insights from in vivo drug metabolism, are the
basis for rule-based and machine learning computational methods
to predict xenobiotic metabolism (Djoumbou-Feunang et al, 2019;
de Bruyn Kops et al, 2019).
In contrast to human drug metabolism, comparable large-scale
data sets for microbiome drug metabolism are mostly lacking, limit-
ing the information available to build predictive models of microbial
drug modifications. To circumvent this limitation, several research
groups have used information on primary and secondary metabo-
lism to infer potential drug modification reactions based on
biochemical reactions and substrate structures (Kl€unemann et al,
2014; Guthrie et al, 2019). Although this approach is consistent with
the chemical similarity between drugs and endogenous compounds,
it suffers from the fact that the genes, biochemistry, and lifestyle of
most gut microbiome members are poorly characterized (Almeida
et al, 2019). This makes it also challenging to define a (standard-
ized) set of microbiome-derived species/strains/enzymes to test
their activity against drug molecules, as it exists for human drug-
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Figure 3. Applications of knowledge gain from studying drug–microbiome–host interactions.
Diagnostics and Prognostics: Microbiome-derived biomarkers (macromolecules, metabolites and compositions) can be used to diagnose diseases, but also for prognosis
of the disease course or to predict treatment success. Protection and Prevention: Various measures can be applied to reduce undesired drug effects on the microbiome or
to suppress chemical drug modifications by intestinal bacteria. With better understanding of the drug–microbiome–host triad, interventions of increased specificity can
be employed (i.e., from fecal transplants to defined restoration therapeutics). Intervention and Modulation: There are both abiotic and biotic approaches to influence the
microbiome, its functional output and consequently drug–microbiome–host interactions. For more detailed explanations, see Box 2.
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cultured complete human fecal communities to test their drug-
metabolizing capacity ex vivo with a panel of up to 438 different
compounds (van de Steeg et al, 2018; Javdan et al, 2020). This
experimental setup has the advantage that microbial community
members do not have to be selected a priori and encompasses
microbial interactions that can impact drug metabolism, as shown
for sequential L-dopa metabolism by two different species (Maini
Rekdal et al, 2019). A challenge of this approach is the uneven
strain distribution in isolated microbial communities, which may
mask and underestimate the metabolic potential of microbes
found at low abundance ex vivo, but may very well be active and
relevant in vivo. Comparable to the described systematic bottom-
up approach to test drug activity on representative panels of
bacteria in isolation (Maier et al, 2018), similar efforts have been
employed to deduce their metabolic activity against a large panel
of drugs (Zimmermann et al, 2019b). Testing microbial communi-
ties or single bacterial strains, up to 65% of the assayed drugs
were metabolized, suggesting that the microbial drug metabolism
is a far more common phenomenon than the few anecdotal exam-
ples collected over the last few decades (reviewed in Wilson &
Nicholson, 2017).
Gaining molecular insights into microbial drug metabolism
Ex vivo drug transformation assays with fecal communities
isolated from different individuals have demonstrated vast inter-
personal differences in the communities’ drug-metabolizing
capacity (Zimmermann et al, 2019b) (Fig 2), which are corrobo-
rated by differences in the drug-metabolizing potential for dif-
ferent bacterial species and strains (Lindenbaum et al, 1981;
Haiser et al, 2013; Zimmermann et al, 2019b). These findings
suggest that the molecular mechanisms of microbial drug trans-
formation need to be identified to predict the drug-metabolizing
capacity of an individual’s microbiome. To identify microbial
enzymes and pathways responsible for drug conversion, several
systems approaches have been applied. Based on the assumption
that metabolic pathways are often transcriptionally induced by
their substrates, transcriptional comparison in the presence and
absence of a given drug can be performed. This approach was
successfully applied to identify the enzymes of Eggerthella lenta
(DSM 2243) and Escherichia coli (K12) that metabolize digoxin
(Haiser et al, 2013) and 5-fluoruracil (preprint: Spanogianno-
poulos et al, 2019), respectively. Gain-of-function and loss-of-
function genetic screens have been combined with mass spec-
trometry-based analytics to systematically identify genes involved
in microbial drug metabolism (Zimmermann et al, 2019a, 2019b)
(Fig 2). Drug-specific chemical probes have also been employed
to probe enzyme activity and to pull down enzymes conveying a
drug conversion of interest, as elegantly applied for the identifi-
cation of beta-glucuronidases (Jariwala et al, 2020). Finally,
computational approaches based on metabolic reaction networks,
comparative genomics of bacterial isolates, or microbiome
composition have been employed to identify possible genetic
factors responsible for drug metabolism (Kl€unemann et al, 2014;
Mallory et al, 2018; Guthrie et al, 2019). Once identified, micro-
bial genes involved in drug metabolism can serve as potential
biomarkers to quantitatively predict the drug metabolic capacity
of a given microbial community (Zimmermann et al, 2019b)
(Fig 3), opening new paths for understanding the impact of
microbial drug metabolism on the host and eventually its role in
the interpersonal variability in drug response.
The role of the host
Interactions between drugs and microbes identified in vitro need to
be validated in the host context, to establish that microbes and drug
meet at relevant concentrations and at the same location. Additional
interactions that are usually not adequately reflected by in vitro
systems but are relevant in the host context include dietary interac-
tions, host drug metabolism, immune responses, and the presence
of endogenous host molecules. Trying to understand the molecular
mechanisms that govern the mutual interactions between micro-
biome and host and trying to explain the compositional adaptations
of the microbial community and altered physiology of the host is at
the very heart of microbiome research. Which environmental and
host factors shape the composition and the functional output of the
microbiome? How do altered microbiome composition and functions
affect the host? Altogether, the consequences of microbiome–drug–
host interactions need to be understood at a molecular level in order
to allow harnessing them and applying them to improve therapy
(Fig 3). Below, we discuss suitable approaches for studying micro-
biome–drug–host interactions (Fig 2).
In vitro approaches
Microbial communities can interact with and affect the host with
peptides/proteins (Gil-Cruz et al, 2019), RNA (Liu et al, 2016), and
metabolites (Uchimura et al, 2018; Koh & B€ackhed, 2020). In the
context of microbiome–drug–host interactions, in particular in the
case of small molecule drugs, metabolite-based interactions seem
natural. Decades of pharmacological research have led to the devel-
opment of in vitro approaches to systematically screen for mole-
cules with a potential effect on the host. Some of which have also
been successfully applied to study metabolic microbiome–host
interactions. Membrane-bound G-protein-coupled receptors (GPCR)
are a prime target for pharmacological interventions, currently
representing more than one-third of the targets for prescribed drugs
(Rask-Andersen et al, 2011). These molecular sensors are omni-
present in mammalian hosts, bind ligands from their environment,
and transduce the signal through molecular cascades to change cell
physiology. Several studies have recently been published employ-
ing high-throughput GPCR activation assays to screen for micro-
biome-produced GPCR ligands (Cohen et al, 2017; Colosimo et al,
2019; Chen et al, 2019). Each of these studies started with metabo-
lites extracted from microbial cultures, which were then tested on
engineered GPCR-reporter cell lines to pinpoint receptor activation.
Strikingly, these studies identified microbiome-derived ligands for
yet uncharacterized, so-called orphan GPCR, which are of particu-
lar interest to potentially expand the drug target space. Following
the same principle, reporter cell lines for the activation of nuclear
receptors, another major target class of drug targets, have been
employed to identify microbiome-derived ligands of human recep-
tors (Estrela et al, 2019). These studies illustrate the applicability
and power of systematic screens based on human cell lines, initi-
ally developed in drug discovery pipelines, to map the chemical
interactome between the microbiome and the host. Following these
examples, similar screening approaches could be applied to the
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analysis of different receptor classes, metabolic activity, and trans-
porter specificity. Clear strengths of these assays include their
reductionist character, mechanistic insights, and high-throughput
capacity, whereas the lack of tissue context and physiological rele-
vance represent obvious limitations.
Intestinal enteroids and organoids overcome this limitation
through differentiation of stem cells into specific intestinal cell
types, such as enterocytes and goblet cells, forming crypt
macrostructures, and encompass intestinal properties, such as
barrier functions (Sato et al, 2009; Yin et al, 2014; Pearce et al,
2018). Such organ culture systems have been used to study the
interactions of human enteric tissue with pathogenic and commen-
sal bacteria (Lukovac et al, 2014; Pleguezuelos-Manzano et al,
2020). Furthermore, these systems have been successfully employed
to study the effect of bacterial surface or secreted molecules, such as
lipopolysaccharides and muramyl-dipeptides (Nigro et al, 2014;
Naito et al, 2017), and of microbiome-derived small molecules, such
as short-chain fatty acids and indolacrylic acid (Park et al, 2016;
Wlodarska et al, 2017; Pleguezuelos-Manzano et al, 2020). Paired
with microfluidic technology, assays co-culturing microbes with
host tissues have been developed to create artificial gut systems on
a chip, enabling systematic measurements under controlled condi-
tions, while maximally mimicking the microbiome–host interface
(Jalili-Firoozinezhad et al, 2019). Such in vitro approaches simulat-
ing microbiome–host interactions can in the future propel our mech-
anistic understanding of drug–microbiome–host interactions.
Altogether, in vitro screening approaches adapted from pharma-
ceutical research and novel technology-driven platforms can both
facilitate the systematic study of drug-microbiome–host interactions.
As shown for GPCRs, such approaches can provide functional
insights into the molecular interactions between microbes and the
host, caused by drug administration. A systematic dissection of the
underlying interactions will pave the way for future in vivo studies
in animal models and clinical settings.
Animal models
Ultimately, we aim at understanding the effects of drug intake on
the whole organism. To this end, invertebrate models can represent
powerful models bridging cell culture systems to complex model
organisms and cohort studies. Both the fruit fly Drosophila melano-
gaster and nematode worm C. elegans, two model organisms with
well-established genetic and genomic resources, are often over-
looked in microbiome research (Norvaisas & Cabreiro, 2018). This
originates from the fact that their associated microbes poorly reflect
the taxonomic and functional diversity of the human microbiome
and that in the case of C. elegans, the impact of microbes on the
host is rather of nutritional than of symbiotic nature (Trinder et al,
2017; Douglas, 2019; Zimmermann et al, 2020). Both organisms
have long-standing traditions of high-throughput screening and
permit a variety of different biomedical readouts ranging from fluo-
rescence reporters of gene function to lifespan, fertility, and behav-
ioral investigations. Furthermore, they both present valuable
advantages for microbiome studies, such as effortless large-scale
production of germ-free or gnotobiotic animals and facile genetic
manipulation, allowing for scalable, cost- and time-efficient studies
of the host–drug–microbiome interface (Diot et al, 2018; Douglas,
2018). These two invertebrate models have proven their worth for
drug discovery research (Pandey & Nichols, 2011; O’Reilly et al,
2014; Fernandez-Hernandez et al, 2016) and have lately been
successfully employed to study interactions at the drug–micro-
biome–host triad.
The low diversity gut microbiome of Drosophila melanogaster
has recently been advantageous in revealing general principles of
antibiotic tolerance that are mediated by metabolic interspecies
interactions (Aranda-Dıaz et al, 2020). In a series of elegant studies,
the C. elegans model allowed to identify bacterial nucleotide meta-
bolism genes that affect chemotherapeutic efficacy on the host
(Scott et al, 2017; Garcıa-Gonzalez et al, 2017) or to understand
how diet can affect metformin’s positive effect on lifespan by gut
microbes (Pryor et al, 2019). In summary, invertebrate models can
be instrumental in pre-selecting the most relevant of the many
possible drug–microbe combinations for a given question.
In contrast to invertebrate models, rodent models have been the
standard for pharmaceutical and microbiome research for decades
(Nguyen et al, 2015). They are suited for pharmacokinetic studies,
allow using established disease models and are more relevant to
human host physiology and microbiota bio-geography. In the micro-
biome field, rodent models are valued for the controlled experimen-
tal manipulation of host (knockouts), microbiome (gnotobiology),
and environment (e.g., diet) and their genetic, anatomical, and
physiological relatedness to humans. These are ideal starting points
to address questions on drug–microbiome–host interactions. Histori-
cally, microbiome-mediated drug metabolism was first discovered in
rats: while the anti-inflammatory drug, salicylazosulfapyridine was
metabolized in conventional animals, the parent compound
remained unchanged in aseptic (antibiotic treated) rats (Peppercorn
& Goldman, 1972). This was the starting point for analogous studies
with other drugs under the assumption of comparable metabolic
functionalities between rodent- and human-associated microbes.
Likewise, many decades later, the combination of genetically engi-
neered gut commensals and gnotobiotic mice provided a system to
quantitatively separate host and microbiome contribution to shared
drug metabolism and assess the role of a single microbial enzyme in
this interaction (Zimmermann et al, 2019a). Other researchers
employed combinatorial therapies, i.e., antibiotics combined with
the drug under investigation to unravel the influence of the micro-
biome on the drug’s pharmacokinetic parameters (Malfatti et al,
2020). Furthermore, rodent models are helpful to investigate possi-
ble therapeutic strategies to mitigate microbiome-induced drug toxi-
city, such as inhibitors of the bacterial beta-glucuronidase enzymes
(Wallace et al, 2010; Bhatt et al, 2020).
There are numerous rodent studies on drug-mediated composi-
tional microbiome changes and their consequences on host physiol-
ogy. A number have examined the short- and long-term effects of
antibiotics (e.g., Cox et al, 2014; Cho et al, 2012; Nobel et al, 2015;
Ruiz et al, 2017). Increasingly, such studies also investigate the
effects of non-antibiotic drugs and diet on drug susceptibility and
recovery (Ng et al, 2019; Cabral et al, 2019; Garland et al, 2020).
While humanized mice (colonized with human microbiota) have
become a cornerstone model to demonstrate causality between
altered microbiome composition and host phenotype in various
diseases, this strategy has so far found little use to assess whether a
drug’s therapeutic effect is mediated through the microbiome. One
exception is again the antidiabetic drug metformin, where fecal
transplantation of metformin-treated patients into germ-free mice
was shown to be sufficient to improve glucose tolerance of recipient
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mice (Wu et al, 2017). This approach provides a powerful tool to
investigate signaling along the drug–microbiome–host axis with
many conceivable ways for improvement (e.g., enrichment and
purification steps, defined microbial consortia, ex vivo incubation of
drugs and microbes) (Walter et al, 2020). Rodent models have
further contributed to our understanding of how the gut microbiome
impacts anticancer immunotherapy by PD-1 (Tanoue et al, 2019),
CTLA-4 blockage (Vetizou et al, 2015; Sivan et al, 2015; Mager et al,
2020) or in cyclophosphamide therapy (Viaud et al, 2013), all result-
ing in findings of high transferability to humans (reviewed in (Zitvo-
gel et al, 2018).
Comparative systems-level analyses of gnotobiotic and conven-
tionally raised mice make it possible to map the effects of microbial
colonization at the organismal scale (Mills et al, 2020). Such
approaches have revealed that numerous host xenobiotic processing
genes, i.e., P450 cytochromes (CYPs), phase II enzymes and trans-
porters are influenced by the microbiome, both at the RNA and
protein level and at various body sites (Selwyn et al, 2016; Kuno
et al, 2016, 2019; Fu et al, 2017). Hence, the microbiome can also
have an indirect impact on drug pharmacokinetics by modulating
xenobiotic metabolism of the host (Dempsey & Cui, 2019).
Well-designed approaches that allow parallelizing the performed
analyses and thus reducing the amount of experimental animals will
tremendously accelerate our understanding of drug–microbiome–
host interactions in both directions, namely those of drugs on
microbes as well as those of microbes on drugs.
Translation to human
A better mechanistic understanding of the drug–microbiome–host
interactions opens the translational possibility to harness the
microbiome and its interpersonal variability in composition to
improve drug treatments in both general and personalized
manners. Such microbiome-based treatments could encompass a
wide range of different applications (Fig 3). Analogous to human
genetic markers guiding drug dosing and potential drug-drug
interaction risks, microbiome biomarkers could be used to predict
drug response and guide treatment regimens, as showcased for
digoxin (Haiser et al, 2013). The identification of microbiome-
encoded enzymes that negatively impact drug response is the
basis for the development of specific inhibitors targeting these
microbial processes. Such inhibitors have been developed to
inhibit microbial metabolism of L-dopa and deglucuronidation of
drug metabolites (Wallace et al, 2010; Maini Rekdal et al, 2019).
Although conceptually interesting, adding additional bioactive
compounds to a given drug formulation comes with new chal-
lenges, such as regulatory hurdles, increased polypharmacy, and
target delivery to the microbiome. Furthermore, targeting micro-
bial enzymes bears the inherent risk of altering microbiome
composition and potentially function. However, this risk also
presents an opportunity. In contrast to the human genomes, the
gut microbiome can be rapidly modified, uniquely allowing both
sides of the patient-drug interaction to be optimized for maximum
therapeutic benefit (Taylor et al, 2019). Interventions such as
dietary changes, antibiotic administration, or fecal microbiota
transplantation (FMT), induce general shifts in microbiome
composition; whereas prebiotics, probiotics and phage therapies
have the potential of introducing targeted changes to the micro-
biome (Box 2). Aside from these interventions which aim at alter-
ing the microbiome composition more permanently, approaches to
temporarily change the functional output of the microbiome have
also been envisioned. Such transient changes could be achieved
through the administration of probiotics that do not stably colo-
nize the gut, but that change gut physiology during their intesti-
nal passage. Another promising avenue is the use of postbiotics,
which are the functional output of beneficial microbes, such as
metabolites, that are administered abiotically.
Box 2. Microbiome modulations
The microbiome has become a primary therapeutic target, with many ongoing clinical trials for multiple medical indications. These studies typically
aim at modulating the microbiome toward a health-promoting state for its human host (e.g., for colorectal cancer (Fong et al, 2020), for atherosclero-
sis (Chen et al, 2020)). The means to do so vary immensely and include a range of interventions that can be separated in biotic and abiotic agents
leading to either global or targeted changes of the microbiome composition. Furthermore, some of these microbiome-targeted therapies aim at per-
manently altering the microbiome, whereas others aim at a transient effect. All of these interventions have in common that they alter the functional
output of the microbial community and hence the microbiome–host interactions. Although, microbiome modulations have not yet been extensively
explored to alter microbiome–drug–host interactions to improve drug response and alleviate adverse effects, we provide an overview of the potential
means to do so (see also Fig 3).
Abiotic interventions consist of dietary changes that shift microbiome composition and prebiotics, which are specific compounds, such as certain sug-
ars, that are preferred by microbiome subpopulations leading to their increase in abundance. Additional abiotic agents include peptides, drugs, and
other xenobiotics, of which antibiotics are intuitive microbiome modifiers. More recently, postbiotics have gained increasing attention (Wegh et al,
2019). The term summarizes a variety of different bioactive fermentation products such as short-chain fatty acids or secondary bile acids. In contrast
to the other agents, postbiotics do not act via compositional microbiome changes but directly mimic an altered functional microbiome output.
Biotic interventions are based on biological agents, such as entire gut communities or specific microbes to modify the function of a person’s micro-
biota. Fecal microbiota transplantations (FMT) transfer the entire microbial gut community from one person to another. Due to the challenges to stan-
dardize and regulate fecal material (Giles et al, 2019), many efforts aim at engineering synthetic communities of defined quality and properties that
can be transplanted. Probiotics describe specific bacterial strains intended for therapeutic purposes (Suez et al, 2019). They are GRAS-certified (gener-
ally regarded as safe) by the Food and Drug Administration and include microbes from different phyla such as Lactobacillus reuteri and Bifidobacterium
casei. Further, probiotic bacteria can be genetically modified to express specific therapeutic properties (e.g., therapeutic proteins (Gurbatri et al, 2020)),
whereas next-generation probiotics are based on microbial isolates from the gut microbiota that are re-inserted, possibly after in vitro modification
(O’Toole et al, 2017). The discovery of increasing numbers of microbiome-associated bacteriophages opens the opportunity to apply phage-therapy to
eliminate unwanted bacterial species and strains from a microbial community in a very specific manner (Sausset et al, 2020). In preclinical models of
colorectal cancer, phages of the tumor-associated Fusobacterium nucleatum have even been used for targeted drug delivery (Zheng et al, 2019).
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Microbiome-targeting interventions could also be employed to
counteract the compositional shifts introduced by medicinal drug
treatments. Autologous fecal microbiota transplantation (auto-FMT)
has improved treatment outcome of patients undergoing allogeneic
hematopoietic stem cell transplantation to reconstitute their micro-
biome after the antibiotic regimens during hematopoietic stem cell
replacement (Taur et al, 2018). Similar approaches could be
applied to treat dysbiosis induced by human-targeted drug treat-
ments. Two recent studies co-administered small molecule drugs
with antibiotics to alleviate the effects of antibiotics on gut
commensals (preprint: Maier et al, 2020; Garland et al, 2020),
providing new ways to avoid or revert the collateral damage of
drug treatment on healthy microbiomes.
Apart from direct drug–microbiome interactions, indirect effects
can also influence microbiome and host functions and interactions.
For example, proton-pump inhibitors (PPI)s are among the drugs
with the most pronounced effect on the gut microbiome composi-
tion (Imhann et al, 2016). It is thought that drug-induced changes in
intestinal physiology, such as increased gastric pH, contribute to
this effect. Analogously, drugs that alter intestinal motility have also
been shown to impact microbiome composition (Vich Vila et al,
2020). The microbiome can also indirectly influence human drug
metabolism and impact pharmacokinetics through regulation or
inhibition of human enzymes. For example, the microbiome-
produced metabolite p-cresol has been shown to competitively
inhibit O-sulfonation enzymes in the liver, which interferes with
acetaminophen clearance (Clayton et al, 2009). Given the complex-
ity of these indirect effects and our current lack of their understand-
ing, systematic approaches are needed to comprehensively map
these interactions at the molecular level.
When translating laboratory findings, in particular from high-
throughput in vitro screens, to human studies, it is essential to
take pharmacokinetic principles into account. For example, oral
drugs, which are still the major form of formulations used, are
typically absorbed in the small intestine where bacterial densities
are rather low. In contrast, the large intestine harbors the most
dense and diverse microbial communities of the human body, but
the absorption capacity of the colon is limited due to reduced
surface area and number of transport proteins. This raises the
question of which bacteria–drug interactions are actually relevant
to drug pharmacokinetics.
To overcome these limitations, physiology-based pharmacoki-
netic (PBPK) models that take into account the microbiome–drug
interactions for pharmacokinetics have been recently developed
(Zimmermann et al, 2019a; Zimmermann-Kogadeeva et al, 2020).
Limited bioavailability, altered intestinal transit and slow release
drug formulations directly influence drug concentrations in the
large intestine, which can affect reciprocal effects between the drug
and the microbiome. In order to directly impact drug pharmacoki-
netics, microbial metabolism and/or bioaccumulation has to occur
in the intestinal tube, where absorption of drug or its metabolites
also takes place. An example of such direct competition between
microbial drug metabolism and intestinal absorption was shown for
L-dopa in the small intestine, which reduces the absorbed drug in a
microbiome-dependent manner (Maini Rekdal et al, 2019). Another
example is the microbial conversion of sorivudine and brivudine to
the liver-toxic metabolite bromovinyluracil in the large intestine,
which leads to increased serum levels and liver toxicity following
large intestinal absorption (Zimmermann et al, 2019a). The micro-
biome-specific PBPK model further predicts that extensive biliary
excretion of drug and drug metabolites can lead to their accumula-
tion in the intestine and hence result in enhanced drug–microbiome
interactions. This provides a route and explanation for non-orally
administered drugs to interact with the gut microbiome, as shown
for the intravenously administered anticancer drug irinotecan (CPT-
11), for which microbiome-caused adverse effects are dose and
treatment limiting (Wallace et al, 2010). CPT-11 is a prodrug that
gets converted to its active compound SN-38 by human enzymes,
before phase II liver reactions (i.e., glucuronidation) inactivate the
compound before biliary secretion into the intestine. The human
gut microbiome encodes for hundreds of different beta-glucuroni-
dases that remove glucuronate from liver-derived (drug) metabo-
lites (Pollet et al, 2017). In the case of SN38, this leads to local
accumulation of the cytotoxic compound resulting in intestinal
complications, such as severe diarrhea. In other cases, microbiome-
produced deglucuronidation products can be either directly or
following additional microbial conversion re-absorbed from the
intestine impacting systemic drug or drug metabolite exposure, as
shown for mycophenolate and clonazepam, respectively (Elmer &
Remmel, 1984; Ishizaki et al, 2012; Zimmermann et al, 2019a).
Although, systematic approaches are needed to comprehensively
map possible drug–microbiome–host interactions at the molecular
level, these examples emphasize the importance of keeping an
organismal view on the results and evaluating their relevance for
translatability to clinics.
Conclusions and future perspectives
Systematic approaches have started to provide new insights into
drug–microbiome–host interactions. A molecular understanding of
the drug–microbiome–host triad will open up strategies to fine-tune
existing clinical drug treatments, improving drug efficacy and reduc-
ing adverse effects. Such strategies could encompass both micro-
biome-inspired compound modifications and modulations of the
microbiome composition. It is conceivable that approaches geared
toward a systematic assessment of drug–microbiome interactions will
become part of preclinical drug development, complementing current
in vitro assays and in silico modeling to predict human drug metabo-
lism and toxicity. In addition to the need of taking into account drug–
microbiome–host interactions for new regulatory requirements, such
knowledge can be key at preclinical drug development stages. It can
improve early compound triaging and target studies on specific
patient groups, foreseeing complications that may arise in the clinical
phase due to interpersonal microbiome differences.
An improved mechanistic understanding of reciprocal drug–
microbiome interactions will also shed light on the potential role of
the microbiome in drug–drug interactions, often observed in
polypharmacy. More broadly, non-drug compounds, such as other
xenobiotics, nutrients, excipients, and even endogenous metabo-
lites, likely influence drug–microbiome–host interactions as well.
Therefore, we first need to systematically map these interactions
and then to understand their mechanistic base to empower future
(personalized) treatments. Big part of the future of drug discovery
lies in harnessing the patients’ microbiome composition and func-
tion for an improved therapeutic outcome.
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